Cell therapy for relapsed B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an experimental cell therapy (RJMty19) for people with B-cell non-Hodgkin lymphoma that has come back or not responded to prior treatments. It aims to see if the therapy is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 65 years old.
- You have a type of B-cell non-Hodgkin lymphoma that is CD19-positive, such as diffuse large B-cell lymphoma (DLBCL) or certain other subtypes.
- Your lymphoma has come back or not responded after at least two prior treatments.
- You have received both an anti-CD20 antibody (like rituximab) and an anthracycline chemotherapy in the past.
- You are in reasonably good health (able to care for yourself, with adequate organ function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lab-made immune therapy (CD19 CAR-T) for adults whose B-cell non-Hodgkin’s lymphoma has come back or did not respond to standard treatments. It may help your immune system attack the cancer cells that carry a specific marker called CD19.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
This trial tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that have come back or not responded to at least two prior treatments. It aims to see if this therapy can help control the cancer.
This trial tests a new type of cell therapy—called CD19 CAR-γδT cells—for adults with B-cell lymphoma that has returned or not responded to standard treatments. The therapy uses your immune system's T cells, specially trained to find and attack cancer cells that carry the CD19 marker.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD19 on your lymphoma cells. It's for people whose B-cell lymphoma has returned or not responded to standard treatments.
This trial tests a new treatment made from your own immune cells (gamma-delta T cells) that are engineered to find and kill CD19-positive lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after at least two standard treatments.
Hear when a new B-cell Non-Hodgkin's Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.